ImageneBio to Participate in Leerink Global Healthcare Conference
Rhea-AI Summary
ImageneBio (NASDAQ: IMA) will participate in the 2026 Leerink Global Healthcare Conference in Miami, March 8-11. Management will join a fireside chat on March 10 at 3:00 PM EST and hold one-on-one meetings. A webcast will be available and archived for 90 days on the company events page.
Positive
- None.
Negative
- None.
News Market Reaction – IMA
In the Feb 26 session, IMA gained 1.64%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Executive appointment | Positive | -0.9% | Named new Chief Medical Officer to lead clinical organization and ADAPTIVE trial. |
| Nov 12 | Earnings & program update | Positive | -0.7% | Reported Q3 results, cash of $142.6M, $75M placement, and IMG-007 progress. |
| Nov 06 | Investor conferences | Neutral | +2.1% | Announced participation in multiple Q4 2025 investor conferences with webcasts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate and financing news has sometimes seen negative price reactions, even when developments appeared strategically positive.
Over the last several months, ImageneBio has focused on rebuilding its platform and visibility. On Nov 12, 2025, it reported Q3 2025 results, highlighted $142.6M in cash after a reverse merger and $75.0M private placement, and emphasized IMG-007 clinical progress. An earlier Nov 6, 2025 update outlined participation in multiple investor conferences. On Feb 10, 2026, the company appointed Dr. Ben Porter-Brown as Chief Medical Officer to drive the Phase 2b ADAPTIVE trial. Today’s conference appearance continues that investor outreach trajectory.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida.
Fireside Date: Tuesday, March 10
Time: 3:00pm EST
Webcast: Linked here and archived for 90 days on events page on the Imagene IR website
About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, IMG-007, is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
Investor and Media Contact:
ir@imagenebio.com
